James Dooner, MD
Ophthalmology · Austin, TXNPI 1962474643
Payments from drug & device makers
Across 221 payments — averaging $2514.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$417K
- Regeneron$126K
- AbbVie$7K
- US Retina LLC$2K
- Genentech USA, Inc.$703
- Regeneron Healthcare Solutions, Inc.$636
- plus $3K from 21 others
Across 1 payment — averaging $14.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$15
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 60 | $417,047 |
| Regeneron | 19 | $125,655 |
| AbbVie(2 entities) | 33 | $6,780 |
| US Retina LLC | 10 | $1,560 |
| Genentech USA, Inc. | 20 | $703 |
| Regeneron Healthcare Solutions, Inc. | 16 | $636 |
| Alimera Sciences, Inc. | 9 | $498 |
| Apellis Pharmaceuticals, Inc. | 12 | $380 |
| Harrow Eye, LLC | 1 | $365 |
| Astellas Pharma US Inc | 10 | $283 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $223 |
| Novartis | 3 | $187 |
| Carl Zeiss Meditec, Inc. | 1 | $176 |
| Genentech, Inc. | 2 | $162 |
| Bausch & Lomb Americas Inc. | 5 | $155 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $137 |
| Astellas Pharma Global Development | 1 | $131 |
| Mallinckrodt Enterprises LLC | 1 | $119 |
| Biotissue Holdings Inc. | 2 | $119 |
| Optovue, Inc. | 1 | $100 |
| Optos, Inc. | 2 | $84 |
| Biogen | 4 | $64 |
| Neurotech Pharmaceuticals, Inc. | 1 | $26 |
| Eyepoint US, Inc. | 1 | $21 |
| Amgen | 1 | $16 |
| Dutch Ophthalmic, USA | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $10 |
How this compares
$555,650 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Austin
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Shelley GhafooriAustin$2.9M
- Thomas WaltersAustin$2.4M
- Philip StoreyAustin$2.1M
- Saradha ChexalAustin$1.8M
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.